What is the diagnostic evaluation and treatment approach for bleeding disorders, such as hemophilia A and B, and von Willebrand disease, in males and females?

Diagnostic Evaluation and Treatment of Bleeding Disorders in Males and Females

Initial Clinical Assessment

For any patient with bleeding symptoms, immediately obtain a structured bleeding history using validated assessment tools focusing on mucocutaneous bleeding patterns (epistaxis, menorrhagia, easy bruising), family history of bleeding disorders, and bleeding after surgical or invasive procedures. 1, 2

Key Historical Features to Elicit:

• Mucocutaneous bleeding: nosebleeds, gingival bleeding, easy bruising, menorrhagia in women, bleeding from minor wounds 3, 2
• Procedural bleeding: dental extractions, surgery, childbirth 3, 2
• Severe bleeding: hemarthroses, hematomas, gastrointestinal/urinary bleeding, CNS bleeding 3
• Family history: critical for diagnosis, particularly in patients with similar symptoms or known bleeding disorders 2

Physical examination should specifically document ecchymoses, hematomas, petechiae, or active bleeding sites. 2

Critical Pitfall:

Do not rely on bleeding history alone in asymptomatic patients requiring surgery—these patients still warrant VWD evaluation for bleeding risk assessment. 1

---

Laboratory Diagnostic Algorithm

Step 1: Initial Screening Tests

Order simultaneously: CBC with platelet count and peripheral smear, PT, aPTT, AND the three mandatory VWD assays (VWF:Ag, VWF:RCo, FVIII). 1, 2

Critical Warning: PT and aPTT alone will completely miss VWD and mild platelet function disorders—they are inadequate for excluding bleeding disorders. 1, 2

Step 2: Pre-Analytical Considerations (Essential for Accuracy)

Before drawing blood: 2

• Ensure atraumatic blood draw
• Minimize patient stress
• Avoid testing during acute illness or pregnancy (these elevate VWF/FVIII levels)
• Oral contraceptives also elevate levels 2

Sample handling requirements: 2

• Transport at room temperature
• Separate plasma from blood cells promptly at room temperature
• If testing delayed >2 hours, freeze at ≤-40°C

Step 3: Interpretation of Initial VWD Assays

Normal reference ranges: 50-200 IU/dL for VWF:Ag, VWF:RCo, and FVIII 2

Diagnostic thresholds: 2

• VWF:RCo <30 IU/dL = Definitive VWD diagnosis
• VWF:RCo 30-50 IU/dL with supportive clinical/family history = Likely VWD

VWF:RCo/VWF:Ag ratio <0.5-0.7 indicates Type 2 (qualitative) VWD rather than Type 1 (quantitative deficiency) 1, 2

Important Considerations:

• ABO blood type matters: Type O individuals have naturally lower VWF levels 2
• VWF:RCo assay has high variability (10-30% coefficient of variation)—repeat testing may be necessary 2
• Stress, exercise, inflammation, and pregnancy can falsely elevate results 2

---

Hemophilia A and B Evaluation

Pre-Treatment Testing Requirements:

For Hemophilia A: 4

• Verify factor VIII coagulant activity levels >5%
• Exclude presence of factor VIII autoantibodies
• Assess serum sodium and aPTT

For Hemophilia B: Similar approach with factor IX assessment 5, 6

Hemophilia severity classification based on factor levels: 7

• Severe: <1 IU/dL
• Moderate: 1-5 IU/dL
• Mild: 5-40 IU/dL

---

Specialized Testing and Referral

Immediate Referral to Hemostasis Specialist Indicated For: 2

• Abnormal initial VWD assay results requiring subtyping
• Strong bleeding history with repeatedly normal tests
• Suspected acquired von Willebrand syndrome (AVWS)
• Need for specialized assays (VWF multimer analysis, VWF:CB, RIPA, FVIII binding assay)

VWF multimer analysis is NOT for initial screening—it is only for subtyping Type 2 variants (2A, 2B, 2M) and must be performed in specialized laboratories. 2

---

Treatment Approach

Von Willebrand Disease (Type 1)

Desmopressin (DDAVP) is first-line treatment for Type 1 VWD and mild Hemophilia A with factor VIII levels >5%. 4

Dosing: 4

• 0.3 mcg/kg actual body weight (maximum 20 mcg) IV over 15-30 minutes
• If preoperative: administer 30 minutes before procedure
• For spontaneous/traumatic bleeding: may repeat every 8-12 hours, then once daily as needed

Mandatory monitoring during desmopressin treatment: 4

• Serum sodium (hyponatremia risk)
• Bleeding time
• Factor VIII coagulant activity
• Ristocetin cofactor activity
• Von Willebrand antigen levels

Critical Safety Requirements: 4

• Initiate fluid restriction during treatment
• Ensure normal serum sodium before starting or resuming treatment
• Monitor blood pressure and pulse during infusion

Tachyphylaxis warning: Response lessens with administration more frequently than every 48 hours; reproducible response returns if given every 2-3 days. 4

Contraindications to Desmopressin: 4

• Moderate-severe renal impairment (CrCl <50 mL/min)
• Hyponatremia or history of hyponatremia
• Heart failure
• Uncontrolled hypertension
• Concomitant loop diuretics or glucocorticoids

Alternative Treatment:

For patients who cannot use desmopressin or have Type 2/3 VWD: plasma-derived concentrates containing factor VIII and von Willebrand factor are required. 5

Hemophilia A and B

Treatment requires rapid replacement of the deficient clotting factor, with dosage dependent on hemorrhagic severity and product used. 5, 6

Early coordination with hematology is critical for optimal emergency management. 6

---

Acquired von Willebrand Syndrome (AVWS)

Consider AVWS in patients with abnormal VWF results and bleeding symptoms WITHOUT personal/family history consistent with hereditary VWD. 3, 1

AVWS is associated with various medical conditions and different mechanisms—laboratory findings mirror hereditary VWD but clinical context differs. 3

---

Sex-Specific Considerations

Von Willebrand disease affects males and females in approximately equal proportions, occurring in up to 1% of the population. 3

In females, menorrhagia and postpartum bleeding are common presentations that warrant VWD evaluation. 3, 8

Hemophilia A and B are X-linked disorders primarily affecting males, though female carriers may have bleeding symptoms if factor levels are sufficiently reduced. 7, 9